Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis

被引：89

作者：

Williams-Herman D. ^{[1
]}

Round E. ^{[1
]}

Swern A.S. ^{[1
]}

Musser B. ^{[1
]}

Davies M.J. ^{[1
]}

Stein P.P. ^{[1
]}

Kaufman K.D. ^{[1
]}

Amatruda J.M. ^{[1
]}

机构：

[1] Merck Research Laboratories, Rahway, NJ

来源：

BMC Endocrine Disorders | / 8卷 / 1期

关键词：

Metformin; Hypoglycemia; Exenatide; Sitagliptin; Vildagliptin;

D O I：

10.1186/1472-6823-8-14

中图分类号：

学科分类号：

摘要：

Background: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust assessment of the long-term safety and tolerability of newer therapeutic agents is of importance. The purpose of this analysis was to assess the safety and tolerability of sitagliptin by pooling 12 large, double-blind, Phase IIb and III studies up to 2 years in duration. Methods: This analysis included 6139 patients with type 2 diabetes receiving either sitagliptin 100 mg/day (N = 3415) or a comparator agent (placebo or an active comparator) (N = 2724; non-exposed group). The 12 studies from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years and that were available in a single safety database as of November 2007. These 12 studies assessed sitagliptin as monotherapy, initial combination therapy with metformin, or add-on combination therapy with other oral AHAs (metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone). Patients in the non-exposed group were taking placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone. This safety analysis used patient-level data from each study to evaluate clinical and laboratory adverse experiences. Results: For clinical adverse experiences, the incidence rates of adverse experiences overall, serious adverse experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed groups. The incidence rates of specific adverse experiences were also generally similar in the two groups, with the exception of an increased incidence rate of hypoglycemia observed in the non-exposed group. The incidence rates of drug-related adverse experiences overall and discontinuations due to drug-related adverse experiences were higher in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in this group. For cardiac- and ischemia-related adverse experiences (including serious events), there were no meaningful between-group differences. No meaningful differences between groups in laboratory adverse experiences, either summary measures or specific adverse experiences, were observed. Conclusion: In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2 years in duration. © 2008 Williams-Herman et al; licensee BioMed Central Ltd.

引用

共 40 条

[31]

Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W., Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, pp. 741-744, (1993)

[32]

Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes, Diabetes Care, 27, pp. 2628-2635, (2004)

[33]

Roberts V.L., Stewart J., Issa M., Lake B., Melis R., Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 27, pp. 1535-1547, (2005)

[34]

Lewin A., Lipetz R., Wu J., Schwartz S., Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: A multicenter, double-blind, randomized, controlled, phase III study, Clin Ther, 29, pp. 844-855, (2007)

[35]

Inzucchi S.E., Oral antihyperglycemic therapy for type 2 diabetes: Scientific review, JAMA, 287, pp. 360-372, (2002)

[36]

Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Et al., Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance, Proc Natl Acad Sci USA, 100, pp. 6825-6830, (2003)

[37]

Amori R.E., Lau J., Pittas A.G., Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis, JAMA, 298, pp. 194-206, (2007)

[38]

Byrd J.B., Shreevatsa A., Putlur P., Foretia D., McAlexander L., Sinha T., Et al., Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema, J Allergy Clin Immunol, 120, pp. 403-408, (2007)

[39]

Yang W., Mohan V., Son H.Y., Liu J., Langdon R.B., Stein P., Sitagliptin monotherapy significantly improves glycemic control and beta-cell function, and is well tolerated in patients with type 2 diabetes in China, India, and Korea (abstract), ASEAN Federation of Endocrine Societies, 24, SUPPL. 1, (2007)

[40]

Dobs A., Goldstein B.J., Wieczorek L., Golm G., Davies M.J., Williams-Herman D., Et al., Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes (abstract), Diabetes, 57, SUPPL. 1, (2008)

← 1 2 3 4 →